This website uses cookies to offer you the best possible user experience. Cookies’ information is stored in your browser and performs functions such as recognizing when you return to our website or helping our team to understand which sections of the website you find most interesting and useful. More information in the privacy policy and cookie policy!
Aroha Sánchez, Labiana Pharmaceuticals S.L. Deputy Technical Director, attends as guest speaker the 15th Seminar on Good Manufacturing Practices Standards for Pharmaceutical Products and APIs.
24.01.2018 LABIANA PHARMACEUTICALS Last December 12th 2017 Aroha Sánchez, our Deputy Technical Director, attended as guest speaker the 15th Seminar on Good Manufacturing Practices Standards for Pharmaceutical Products and APIs organized by the Department of Health of Generalitat of Catalonia.
She was invited to share the experience of a pharmaceutical laboratory about the implementation of the ICHQ3D, a guideline for elemental impurities. The deadline of its implementation involving pharmaceutical products currently on the market was end of 2017.
General Council of Pharmaceutical Associations of Spain, Faculty of Pharmacy of the University of Barcelona, Farmaindustria, AEFI (Spanish Association of Pharmacists of the industry, Catalan branch) and AFAQUIM (Spanish Association of Manufacturers of Fine Chemical Products) are some of the organizations which also attended the seminar.
During the presentation Aroha Sánchez was able to share the strategy and the project of global implementation of the ICHQ3D guideline. She also addressed other points of interest such as the procedure established, using a practical case as an example, with conclusions and future perspectives.
Aroha Sánchez was a guest speaker together with other experts in the field, such as consultants of the chemical-pharmaceutical industry and experts on manufacturing of active pharmaceutical ingredients.
The seminar was undoubtedly a unique opportunity to share our experience with other laboratories and organizations as well as a chance to address one of the many legislative developments faced nowadays by the pharmaceutical industry.